Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients

Abstract

The present study was designed to explore whether serum stromal cell-derived factor-1 (SDF-1) levels were associated with diabetic kidney disease (DKD). Serum SDF-1 levels were measured by sandwich ELISA. Patients with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 or a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g for 3 months were identified as having DKD. Among the recruited type 2 diabetic patients, 18.71% (n = 32) were found to have DKD, and the serum SDF-1 levels of these patients were higher than those of patients without DKD (p < 0.05). Serum SDF-1 levels were positively correlated with cystatin C levels, the UACR and DKD incidence (r = 0.330, 0.183 and 0.186, respectively, p < 0.05) and inversely related to eGFR (r = -0.368, p < 0.001). After adjusting for other clinical covariates by multivariate logistic regression analyses, serum SDF-1 levels were found to be an independent contributor to DKD, and the odds ratio (95% confidence interval) was 1.438 (1.041-1.986). Furthermore, receiver operating characteristic analysis revealed that the optimal SDF-1 cutoff value for indicating DKD was 5.609 ng/mL (its corresponding sensitivity was 82.00%, and specificity was 46.90%). Our results demonstrated that serum SDF-1 levels were closely associated with DKD and could be considered a potent indicator for DKD in patients with T2D.

Association of serum stromal cell-derived factor 1 levels with EZSCAN score and its derived indicators in patients with type 2 diabetes

“…It has been confirmed that elevated SDF-1 levels can promote the onset and progression of T2D by inducing islet inflammation [13] and mediating insulin desensitization in adipocytes [14]. Our previous study demonstrated that serum SDF-1 levels are closely related to hyperglycemia, hypercoagulability, and inflammation in patients with T2D [15]. Since chronic complications of diabetes share a common pathogenesis [16], we speculated that serum SDF-1 levels may be closely related to CAN and cardiovascular disease (CVD) in patients with T2D.…”

Butyrate alleviates renal inflammation and fibrosis in a rat model of polycystic ovarian syndrome by suppression of SDF-1

“…Stromal cell-derived factor-1 is a CXC chemokine and the major ligand for chemokine receptor type 4 (CXCR4), a seven transmembrane domain G-protein coupled receptor that is found in endothelial cells, and also localized in the podocytes and distal tubular cells of the kidney with multiple contextual functions [ 10 ]. However, hyperproliferation of SDF-1 has been reported in the development of glomerular disease or kidney disease, especially in metabolic-related disease such as type 2 diabetes mellitus [ 11 ]. In addition, elevated level of SDF-1 induces inflammation through the activation of a non-canonical NF-κB signaling pathway in the kidney [ 12 ], promoting glomerular sclerosis, loss of podocytes and apoptosis [ 13 ].…”